Blood & Cancer-logo

Blood & Cancer

Health & Wellness Podcasts

The official podcast feed of MDedge Hematology-Oncology, part of the Medscape Professional Network. On Thursdays, Dr. David Henry interviews key opinion leaders and rising stars in hematology and oncology. The information in this podcast is provided for informational and educational purposes only.

The official podcast feed of MDedge Hematology-Oncology, part of the Medscape Professional Network. On Thursdays, Dr. David Henry interviews key opinion leaders and rising stars in hematology and oncology. The information in this podcast is provided for informational and educational purposes only.

Location:

United States

Description:

The official podcast feed of MDedge Hematology-Oncology, part of the Medscape Professional Network. On Thursdays, Dr. David Henry interviews key opinion leaders and rising stars in hematology and oncology. The information in this podcast is provided for informational and educational purposes only.

Language:

English

Contact:

2402212400


Episodes

Optimizing CAR T-cell therapies in lymphoma: Improving response, fighting cytokine release syndrome, and identifying mechanisms of resistance

4/15/2021
Studies have shown that chimeric antigen receptor (CAR) T-cell therapies produce responses in patients with relapsed/refractory B-cell lymphomas, but researchers continue to look for ways to improve efficacy, decrease toxicity, and overcome treatment resistance. Leslie Kean, MD, PhD, of Boston Children’s Hospital, discusses some of this research with host David H. Henry, MD, in this episode. Dr. Kean outlines four recent studies of CAR T-cell therapies in lymphoma. The studies were...

Duration:00:25:36

Trends in genetic testing for breast and ovarian cancer: Undertesting and racial/ethnic disparities persist

4/8/2021
Researchers have tracked the evolution of genetic germline testing in women with breast or ovarian cancer in recent years and reported the results in the Journal of Clinical Oncology. Study author Allison W. Kurian, MD, of Stanford (Calif.) University, describes the group’s findings (https://bit.ly/31RaSGR) to guest host Alan Lyss, MD, subprincipal investigator emeritus for Heartland Cancer Research NCORP, in this episode. Study rationale and methods Results by hypothesis Hypothesis 1:...

Duration:00:26:42

Improving cancer screening in the COVID era: Drive By Flu-FIT allows for socially distanced colorectal cancer screening

4/1/2021
A program called Drive By Flu-FIT has allowed for socially distanced colorectal cancer (CRC) screening during the COVID-19 pandemic. Armenta Washington, senior research coordinator at the University of Pennsylvania, describes the program to guest host Alan Lyss, MD, subprincipal investigator emeritus for Heartland Cancer Research NCORP, in this episode. What is Drive By Flu-FIT? How does Drive By Flu-FIT work? Results: High return...

Duration:00:31:21

Unpacking von Willebrand disease guidelines: Dr. Paula James talks diagnosis and pre-procedure prophylaxis

3/25/2021
Earlier this year, clinical practice guidelines for the diagnosis and management of von Willebrand disease (VWD) were published in Blood Advances. The guidelines (https://bit.ly/2OIfKLE) are a collaborative effort from the American Society of Hematology, the International Society on Thrombosis and Haemostasis, the National Hemophilia Foundation, and the World Federation of Hemophilia. Guideline author Paula James, MD, of Queens University, Kingston, Ont., reviews some of the...

Duration:00:18:38

FDA approvals in hematology and oncology, Part II: New oral formulations, RET and MET inhibitors, and CAR T-cell therapies

3/18/2021
We continue our review of drugs recently approved by the Food and Drug Administration (FDA) in the hematology/oncology space. In part 1 of our review, David M. Mintzer, MD, of Pennsylvania Hospital, highlighted 11 therapies, including newly-approved treatments and new indications for older drugs. Part 1 was published Feb. 18 (https://bit.ly/38JR782). Now, in part 2, Dr. Mintzer tells host David H. Henry, MD, about another 11 therapies recently approved by the FDA, including monoclonal...

Duration:00:20:15

How I treat CLL and MCL: From ‘watch and wait’ to BCL2 and BTK inhibitors, CAR T-cell therapy, and transplant

3/11/2021
Treatments for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) have advanced in recent years, with more new developments on the horizon. James Gerson, MD, of the University of Pennsylvania, Philadelphia, reviewed some of these advances and future directions while describing how he would treat three patients. Host David H. Henry, MD, posed the following cases for consideration. Case 1 In a 75-year-old male with no comorbid illness, routine blood work revealed a WBC count...

Duration:00:22:50

COVID-19 vaccination in cancer patients: Who should be vaccinated and when?

3/4/2021
When should cancer patients receive a COVID-19 vaccine? The National Comprehensive Cancer Network (NCCN) has issued recommendations to provide guidance on the topic. Guideline author Steven Pergam, MD, of Fred Hutchinson Cancer Research Center, Seattle, explains NCCN’s recommendations to host David H. Henry, MD, in this episode. Prioritization Transplant and cellular therapy Hematologic malignancies Antibody response Solid tumor malignancies These guidelines are available for...

Duration:00:30:39

Managing pain in sickle cell crisis with Dr. Ifeyinwa Osunkwo

2/25/2021
Ifeyinwa (Ify) Osunkwo, MD, MPH, joins us to talk about her approach to pain management in patients suffering from sickle cell crisis as well as the cognitive and behavioral effects of long-term opioid use in these patients. She and our host David H. Henry, MD, cover these topics and more in this episode. Dr. Osunkwo is a professor of medicine at Atrium Health and the director of the Sickle Cell Enterprise at the Levine Cancer Institute, part of Atrium Health, in Charlotte, N.C. Management...

Duration:00:26:04

FDA approvals in hematology and oncology: Novel agents and new tricks for old drugs

2/18/2021
In this episode, we review drugs recently approved by the Food and Drug Administration in the hematology/oncology space. David M. Mintzer, MD, of Pennsylvania Hospital, joins host David H. Henry, MD, to highlight some first-time approvals and new indications for older drugs. Approvals in 2020 Pembrolizumab (Keytruda) was approved for a range of new indications last year, including: https://bit.ly/2OKw8uF.https://bit.ly/2NCddkX.https://bit.ly/2ZobcMc.https://bit.ly/3ashYGV. Avelumab...

Duration:00:23:23

NCI-MATCH trial reveals actionable mutations and matches cancer patients to targeted therapies

2/11/2021
The NCI-MATCH trial was designed to reveal mutations in underexplored cancer types, allowing researchers to match patients to appropriate targeted therapies. Study investigator Alice P. Chen, MD, from the National Cancer Institute, reviews the goals and results of NCI-MATCH with host David H. Henry, MD, in this episode. Trial details Matching patients to treatment Results J Clin Oncol. 2020 Nov 20;38[33]:3883-94https://ecog-acrin.org/nci-match-eay131-findingsJ Clin Oncol. 2020 Aug 06....

Duration:00:20:07

COVID-19 vaccine 101: Dr. Drew Weissman discusses mechanisms, efficacy, and vaccinating patients with cancer or HIV

2/4/2021
How do the various COVID-19 vaccines work, and when should patients be vaccinated? We tackle these topics and more in this episode. Our host David H. Henry, MD, is joined by Drew Weissman, MD, PhD, a professor at the University of Pennsylvania, Philadelphia. Dr. Weissman codeveloped the messenger RNA (mRNA) technology being used in the COVID-19 vaccines produced by Pfizer/BioNTech and Moderna. History of mRNA vaccines Immunology and vaccines COVID-19 vaccine reactions Variants and...

Duration:00:23:44

Barriers to clinical trial enrollment for patients with gynecologic cancers: Why patients don’t participate and how to improve enrollment

1/28/2021
The greatest barrier to clinical trial enrollment is patients not knowing an appropriate trial exists, according to a survey of gynecologic cancer survivors. The most common reason survey respondents gave for not enrolling in clinical trials was that their medical team didn't tell them about any trials. Annie Ellis and Mary (Dicey) Jackson Scroggins – who are both patient advocates and ovarian cancer survivors – conducted this survey and presented the results at the Society of...

Duration:00:21:36

Convalescent plasma for COVID-19, race linked to cancer-associated thrombosis risk, iron deficiency common in pregnancy, and more from ‘Best of ASH’

1/21/2021
New studies have shed additional light on how convalescent plasma may affect patients with COVID-19, how blood type impacts bleeding risk, the effects of race on cancer-associated thrombosis, and iron deficiency in pregnancy. These studies were presented as part of the “Best of ASH” session at the 2020 annual meeting of the American Society of Hematology. Alisa S. Wolberg, PhD, of the University of North Carolina at Chapel Hill, who cochaired the session, reviews these studies with host...

Duration:00:18:58

Thrombosis research from ASH 2020: Khorana score falls short in cancer study, factors predict VTE in cancer patients with COVID-19, and antithrombotics don’t affect severe COVID outcomes

1/14/2021
Three studies revealed new findings on thrombosis in patients with cancer and/or COVID-19. These studies were presented at the 2020 annual meeting of the American Society of Hematology. One study suggested the Khorana score may be ineffective for predicting venous thromboembolism (VTE) in cancer patients. Another study revealed factors that can predict VTE in patients with cancer and COVID-19. And a third study indicated that antithrombotic agents don’t improve outcomes in patients with...

Duration:00:24:30

Highlights from SABCS 2020: New data on CDK4/6 inhibitors, omitting chemotherapy and radiotherapy, underreporting toxicity, and predicting outcomes in breast cancer

1/7/2021
A number of groundbreaking and practice-changing studies were presented at the San Antonio Breast Cancer Symposium 2020. The RxPONDER, ADAPT, and PRIME-2 trials revealed patients who can forgo chemotherapy or radiotherapy, monarchE and PENELOPE-B showed conflicting results with CDK4/6 inhibitors, one study indicated that a new tool can guide adjuvant chemotherapy, and another study suggested that circulating tumor cells (CTCs) can predict overall survival (OS). Alan P. Lyss, MD,...

Duration:00:52:12

Best of Blood & Cancer 2020

12/24/2020
In this episode, we bring you clips from the best Blood & Cancer shows of 2020. Blood & Cancer will be back with new episodes in 2021. https://bit.ly/3h7aWZM https://bit.ly/37GhV8Q https://bit.ly/3nS4592 https://bit.ly/3rizmnM https://bit.ly/37EIbkg * * * For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd

Duration:00:40:23

SABCS 2020: More women may forgo chemo, surgery's role in opioid use, and pregnancy after breast cancer

12/22/2020
News from SABCS 2020: https://bit.ly/2LIYjZthttps://bit.ly/3gSWfJFhttps://bit.ly/2KwlhCx Email Blood & Cancer at podcasts@mdedge.com.

Duration:00:08:22

How does COVID-19 affect patients with hematologic malignancies? The ASH registry provides some answers

12/17/2020
The ASH Research Collaborative COVID-19 Registry for Hematology was established earlier this year to study patients with hematologic malignancies diagnosed with COVID-19. Now, the registry also includes patients with nonmalignant hematologic disorders and hematologic manifestations of COVID-19. William Wood, MD, of the University of North Carolina at Chapel Hill, recently presented data from the registry at the ASH Annual Meeting. In this episode, Dr. Wood tells host David H. Henry, MD, how...

Duration:00:27:02

News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD and no benefit seen with tranexamic acid in patients with blood cancers and severe thrombocytopenia

12/15/2020
News from ASH 2020: https://bit.ly/2K3Mah1https://bit.ly/3gT4kyghttps://bit.ly/381f1uthttps://bit.ly/3gKuZgx Email Blood & Cancer at podcasts@mdedge.com

Duration:00:10:11

How I treat GVHD: Dr. James Ferrara explains how biomarkers can predict outcomes and guide the treatment of acute GVHD

12/10/2020
A pair of biomarkers are being used to guide treatment and predict mortality in patients with graft-versus-host disease (GVHD), according to James L.M. Ferrara, MD, DSc, of the Icahn School of Medicine at Mount Sinai, New York. In this episode, Dr. Ferrara explains how measuring these biomarkers – REG3-alpha and ST2 – can prevent over- and undertreatment of acute GVHD. The biomarkers have also been shown to predict nonrelapse mortality more accurately than a change in clinical...

Duration:00:29:15